Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Emend for Injection
Fosaprepitant is a prodrug of aprepitant, a neurokinin-1 (NK-1) receptor antagonist. It is used to prevent nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin-based regimens. Fosaprepitant belongs to the class of antiemetics and works by blocking the action of substance P, a neurotransmitter involved in the vomiting reflex.
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy.
Outcome:
Increased fosaprepitant levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Increased midazolam levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Potential for slight decrease in digoxin levels
Mechanism:
Induction of P-gp
Most likely new formulation: Extended-release oral formulation (2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that fosaprepitant will maintain its approved status for CINV prevention in the next 5 years.
Antiemetic
Quinuclidine derivative